Semagacestat’s fall: Where next for AD therapies?

Nature Medicine

Volumn 19, Issue 10, 2013, Pages 1214-1215

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AZEPINE DERIVATIVE; N2-((2S)-2-(3,5-DIFLUOROPHENYL)-2-HYDROXYETHANOYL)-N1-((7S)-5-METHYL-6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-L-ALANINAMIDE; SECRETASE;

ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; HUMAN; METABOLISM;

ALANINE; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; AZEPINES; HUMANS;

EID: 84893778864     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3365     Document Type: Article

References (16)

1. Doody, R.S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 369, 341–350 (2013).
2. Fleisher, A.S. et al. Phase 2 safety trial targeting amyloid β production with a g-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031–1038 (2008).
3. Portelius, E. et al. A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer’s disease. Alzheimers Res. Ther. 2, 7 (2010).
4. Scheuner, D. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864–870 (1996).
5. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144 (2010).
6. Levitan, D. & Greenwald, I. Facilitation of lin-12–mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer’s disease gene. Nature 377, 351–354 (1995).
7. Xia, X. et al. Loss of presenilin 1 is associated with enhanced β-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 10863–10868 (2001).
8. van Es, J.H. et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959–963 (2005).
9. Wong, G.T. et al. Chronic treatment with the γ-secretase inhibitor LY-411, 575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876–12882 (2004).
10. Kuhn, P.H. et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 31, 3157–3168 (2012).
11. Willem, M. et al. Control of peripheral nerve myelination by the β-secretase BACE1. Science 314, 664–666 (2006).
12. Cheret, C. et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J. 32, 2015–2028 (2013).
13. Jonsson, T. et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488, 96–99 (2012).
14. Savva, G.M. et al. Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302–2309 (2009).
15. 42 immunisation in Alzheimer’s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216–223 (2008).
16. 42 immunization. Neurology 61, 46–54 (2003).